<DOC>
	<DOCNO>NCT00938444</DOCNO>
	<brief_summary>This protocol design evaluate BRADA ABILHAND questionnaires rheumatoid arthritis ( RA ) patient treat effective therapy . Patients moderate severe RA treat tocilizumab ask complete BRADA ABILHAND questionnaires screen , baseline , 12 week 24 week treatment . All assessment questionnaire daily clinical practice ( global assessment disease activity patient , Health Assessment Questionnaire ( HAQ ) , SF36 questionnaire , measurement ESR CRP DAS 28 calculation ) , also use evaluate questionnaire .</brief_summary>
	<brief_title>Evaluation BRADA ABILHAND Questionnaires</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>patient moderate severe RA . Inadequate response earlier optimal use minimum two DMARDs ( disease modify antirheumatic drug goldsalts , salazopyrine , leflunomide , methotrexate ( MTX ) ) far one two used DMARDs MTX exception document intolerance despite association folic acid , administer IM oral minimum 3 month minimal dose 15mg/week . DAS 28 score â‰¥ 5.1 For drug register treatment moderate severe RA commercially available constitute satisfactory treatment patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Patients moderate severe RA</keyword>
</DOC>